Introduction
Cytomegalovirus (CMV) infects between 40-100% of adults throughout the world, depending primarily on socio-economic status. However, other relevent factors include the degree and form of sexual activity such that, in the UK, homosexual men have a seroprevalence of 80% compared with 42% of sexually active male heterosexuals.' These individuals may present to genitourinary medicine clinics with CMV-related symptoms, most of whom will be infected with HIV.
As a member of the herpes group of viruses, infection with CMV leads to a state of latency with the capacity to reactivate at any time. Primary infection in the immunocompetent is usually asymptomatic but may be associated with a mononucleosis-type illness. Reactivation is of major consequence in those who are immunocompromised in whom it may be associated with retinitis, colitis, pneumonitis or encephalitis, all of which carry significant morbidity.2
The availability of effective anti-CMV therapy has heightened the requirement for rapid, sensitive methods of CMV detection, and these will be discussed in detail. By contrast, serological diagnosis of CMV infection (ie antibody determination) depends on a functional immune system and, we believe, plays little role in CMV diagnosis in the immunocompromised individual. Despite the severe symptomatology associated with CMV, it is important to realise that infection does not equate with disease. Thus, virological evidence of CMV infection must always be interpreted within the clinical context before treatment is considered.
Virus isolation
The detection of CMV in clinical specimens by growth in conventional cell culture (CCC) remains the "gold standard" against which any new detection system must be compared. Human CMV is highly species specific and thus will only grow in human fibroblasts, a cell line commonly employed in clinical virology laboratories.' The characteristic CMV cytopathic effect (CPE) consists of small round or elongated foci of rounded, enlarged refractile cells (fig 1) , which usually develop 2-3 weeks following inoculation, but may take up to 6 weeks. The clinical specimens most commonly inoculated are urine, saliva (or throat swab taken into viral transport medium) and the "buffy coat" component of whole blood which has been taken into preservative-free heparin. However, CMV can be isolated from a wide range of tissues, and biopsy samples taken into viral transport medium and subsequently homogenised prior to inoculation are especially valuable for the diagnosis of invasive disease. Rapid transport of samples from ward to laboratory is essential since CMV is a labile virus. If this is not possible the sample should be stored at 4'C and never frozen. this method may be more labour intensive than DEAFF, it does allow for centrifugation of the inoculated cell monolayer which can increase the sensitivity of viral detection.8 "Centrifugal enhancement" is a relatively specific property of CMV cultures, and increase in infectivity is greatest at low (1000 g) rather than high speed centrifugation. The precise mechanism of centrifugal enhancement remains unclear.9
Antigen In situ hybridisation has been shown to detect CMV DNA or RNA in tissue specimen sections, even in cells that do not appear to be infected by standard histological criteria.2122 However, in comparison with conventional and rapid cell culture, it was shown to be the least sensitive for the detection of CMV DNA in bronchoalveolar lavage samples. 23 The dot-blot method of hybridisation, requiring an initial extraction ofnucleic acid from clinical samples, has been reported to be a more reliable method for CMV detection, especially from urine.2425
The above techniques have now been superseded by the polymerase chain reaction (PCR). This is a method for in vitro amplification of specific gene sequences prior to detection. It requires the presence of specific primers complementary to DNA sequences on either side of a target CMV DNA segment of known size. By repeated cycles of heating and cooling, in the presence of a heat stable DNA polymerase, a single gene copy may be amplified up to one million fold. This may subsequently be detected following electrophoresis of the PCR mixture in the presence ofa nucleic acid stain, since the gene is of known molecular size; however, confirmation may be made by subsequent hybridisation with a labelled oligonucleotide probe.20 It follows that the major benefit of PCR is its high sensitivity for CMV detection. Conversely, PCR is highly susceptible to contamination by extraneous viral material, a problem of particular concern to a diagnostic virology laboratory in which CMV is commonly grown to a high titre. The improved sensitivity of PCR compared to other methods of CMV diagnosis has been documented for viral detection in blood and urine samples, in HIV infected as well as other immunocompromised patients.2129 However, a possible limitation of this high degree of sensitivity is based on the knowledge that normal viral replication gives rise to a large proportion of defective viral particles, unable to take part in further productive infection. It is likely that such genomes would be detected by a PCR technique, despite the fact that their presence does not necessarily denote active viral infection, nor constitute evidence of disease. Formal assessment of prognostic value of any given PCR method is therefore mandatory. Alternatively, a discriminative reporting of PCR results may be of more use than merely a positive or negative result. Of interest is the recent development of a quantitative PCR method for detection of CMV in clinical samples,'0 which has been used to show that a high CMV genome copy number in urine is more likely to be associated with CMV disease than a low copy number (personal communication; JC Fox, PD Griffiths and VE Emery).
Serology
Serological diagnosis of viral infection normally depends on the detection of a seroconversion, a four fold or greater increase in titre of antibody, or the presence of specific circulating IgM, and sensitive methods are now widely available for the detection of CMV IgG and IgM. The immunocompromised patient, however, is characterised by an inability to mount normal immune responses, especially to a reactivation of latent infection, as is often the case with CMV.`"3 The disadvantages of serological methodology over virus detection are therefore lack of sensitivity, and delay in diagnosis, since the serological changes which do occur in response to infection are often late in onset.'2 The measurement of local specific antibody production, such as has been carried out in bronchoalveolar lavage fluid from transplant recipients with CMV pneumonitis, has also been shown to be ofno diagnostic benefit.'2
In HIV infected individuals the most useful role of serology is the determination of CMV IgG status, which allows categorisation of patients into those who are liable to CMV reactivation and those who are not.
Diagnosis of CMV disease
As discussed above CMV infection does not equate with CMV disease. A diagnosis of disease depends on a combination ofvirological and clinical data together with an assessment of the individual's risk factors, such as the degree of this immunocompromise. Close cooperation between the clinician and virologist is therefore essential. Some important aspects in the diagnosis of CMV related disease in HIV infected individuals are discussed below.
Gastrointestinal disease
Although almost all areas ofthe gastrointestinal tract may be infected with CMV, the most common manifestation is diarrhoea due to CMV colitis. Since many other opportunistic and non-opportunistic infections may present in an identical manner, a biopsy diagnosis is usually required before onset oftreatment. The ascending colon has previously been thought to be the most common site of CMV infection";
however, other workers have demonstrated rectum and sigmoid colon involvement as well, with a relative sparing of the transverse colon."' It is essential that investigations include a colonscopy with multiple biopsies taken from ascending, transverse and the rectosigmoid region. Symptoms from other areas of the GI tract also require an analysis of relevant biopsy samples for a diagnosis of CMV infection.
Central nervous system disease Encephalitis and myelitis have been attributed to CMV infection.'536 However, although histological involvement of the brain suggestive of CMV infection frequently is noted in post mortem material from AIDS patients, 35 and CMV antigens and nucleic acid is detected in nervous tissue, it remains difficult to ascribe disease to CMV infection.37 This problem is compounded by the known neurotropism of HIV itself. In clinical practice, a brain biopsy is often undesirable, and in those with otherwise unexplained neurological symptoms we suggest the sampling of CSF, whole blood and other peripheral sites for CMV detection which, if positive, may support a clinical diagnosis of CMV disease.
Retinitis
The diagnosis of retinitis is based solely on ophthalmological examination following the onset of symptoms.'8 The eyes of AIDS patients must therefore be examined regularly, in order that treatment can be initiated promptly. These individuals often require long term maintenance therapy. Although retinitis is often suffered by those with disseminated CMV disease, the detection of CMV elsewhere should have no bearing on the diagnosis of CMV retinitis. Pneumonitis CMV pneumonitis is a common and severe problem following organ transplantation requiring urgent treatment and is diagnosed by detection of CMV in bronchoalveolar lavage (BAL) fluid. '9 In contrast, although CMV is often isolated from lavage fluid of AIDS patients with respiratory signs and symptoms, either alone or in association with other infectious agents, it rarely causes disease.' It is thought that CMV pneumonitis is mainly mediated by immuno-pathological mechanisms, rather than the viral lytic infection which causes damage in other tissues.4' As such, the development of pneumonitis depends to some extent on a functional immune response to CMV. AIDS patients commonly have very low CD4 counts when CMV is detected, and may not be able to mount such a response. We therefore recommend that BAL samples are sent for CMV detection in these patients but that a diagnosis of CMV pneumonitis only be made following the failure of treatment for other suspected opportunistic chest infections, and where the CD4 count is greater than 100 x 106/1.42
Prognostic value of CMV detection The severe nature of CMV infection in transplant recipients has led to attempts to define risk factors for disease. One approach has been for regular surveillance cultures, from multiple sites, to be undertaken for CMV detection during the high risk post-transplant period. Such studies have shown that CMV isolated from blood, but not urine or saliva, is associated with an increased risk of subsequent CMV disease.4 ' CMV viraemic individuals may then be given pre-emptive therapy prior to onset of symptoms, or be closely observed such that treatment can be initiated early if disease develops. A similar prospective study carried out in 71 AIDS patients showed that 50% of those with CMV viraemia later developed organ disease compared with 9% of nonviraemic patients, over a mean follow-up period of 16 months. 45 Further studies are now required in order to determine if anti-CMV pre-emptive therapy can be allocated to AIDS patients on a similar basis (in those who are CMV viraemic) thereby preventing a major cause of morbidity and mortality in this group of individuals. Conclusion CMV related pathology in AIDS patients is being observed to an increasing extent, both because of the growth of this population, and the fact that they are surviving for a longer period. With the availability of effective anti CMV treatments, rapid methods of CMV diagnosis are required in order that early initiation of such treatment can occur. Conventional cell culture remains the gold standard of diagnosis, however rapid culture techniques, and antigen detection have been shown to be both sensitive and specific and are widely used because of their rapidity. Of the array of methods available for detecting CMV genomes in clinical specimens, the polymerase chain reaction is most likely to find its way into diagnostic use. Its major advantage is sensitivity; however, it is also quick, and need not require the use of radioactivity. A full comparison of PCR with other established methods of CMV diagnosis in a clinical setting is awaited.
In conjunction with sensitive detection systems, another potential development for the future is the introduction of prospective diagnosis, or surveillance for CMV infection in AIDS patients. This would allow for treatment options to be considered prior to the onset of symptomatology, and lead to a further enhancement in the quality of life of these individuals.
